Rhythm Pharmaceuticals heads into its third-quarter report with a peculiar disconnect. Last quarter, management laid out a hypothalamic obesity launch that was beating its own Bardet-Biedl syndrome playbook on nearly every early metric, yet the stock has slid about 11% since then while the broader market went nowhere. That gap sets up a report that needs to show the Incivri ramp is translating into dollars at the pace the Street now assumes, not just into start forms and prescriber counts.

Consensus calls for revenue of roughly $84.5 million, up nearly 65% from $51.3 million a year ago and about 18.5% above the $71.3 million posted last quarter. The expected loss of $0.68 per share would be an improvement from $0.73 in the second quarter and $0.82 a year earlier. The sequential revenue bar is the important one. It essentially asks Rhythm to repeat the 19% jump it delivered last quarter. There is some cushion: the second quarter absorbed a one-time $3.8 million retrospective French pricing charge, so the underlying base was closer to $75 million, and a clean international number should help. Even so, the estimate implies continued steep US growth rather than a plateau.

The operational evidence that matters most comes straight from last quarter's call. Start forms climbed from more than 150 in the launch's first six weeks to more than 400 after 14 weeks, and unique prescribers roughly tripled to about 300, with around a fifth writing for more than one patient. Start forms are leading indicators, though, and the key question now is conversion. Patients on reimbursed therapy grew more than 20% sequentially last quarter, versus 8% to 10% in prior periods. If that rate holds or accelerates, the launch narrative is validated. A slip back toward the old cadence would suggest the early surge was front-loaded demand working through a slower reimbursement funnel. Payer progress is the companion metric: Rhythm disclosed HO-specific policies covering about 25% of Medicaid and 35% of commercial lives, with no GLP-1 step edits. Meaningful expansion there, plus gross-to-net holding near the improved 86% level, would support both volume and pricing.

Costs provide a second check. Management trimmed full-year non-GAAP operating expense guidance to $363 million to $397 million, attributing the cut to manufacturing timing for next-generation assets RM718 and bivomelagon slipping into early 2027, with clinical timelines unchanged. Reaffirming that range and the bivomelagon Phase 3 start around year-end would confirm the reduction was about timing, not retrenchment. SG&A, which reached $67.4 million as the field force split into dedicated HO and BBS teams, will show how much operating leverage the launch is generating. Updates on the Japan approval targeted for year-end and the Germany launch planned for the first half of 2027 also bear on whether international sales can grow beyond Europe's pricing friction.

Sentiment has soured noticeably, moving from mildly bearish ahead of the last report to more clearly bearish now. The shares sit near $89, below the 200-day moving average around $97 and only about 4.5% above the post-earnings low of $85.38, a long way from the $119.75 high. That positioning suggests skepticism is already priced in, which lowers the bar for a relief move on solid numbers but also signals little patience for a shortfall.

Ultimately, this report hinges on whether reimbursed patient growth keeps pace with the impressive top-of-funnel demand Rhythm showcased last quarter. If revenue lands near the estimate with reimbursed patients still climbing at a 20%-plus clip, the improving story remains intact and the recent selloff looks like an overreaction. If conversion lags, the Street's sequential assumption will look too aggressive.